NON SMALL CELL LUNG CANCER METASTATIC

This study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumor…

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…

This phase 2 trial tests whether using a proteomic test (PROphet CB) and a toxicity assessment (CARG-TT) to guide first-line treatment can improve 12-month survival in people with advanced non-small cell lung cancer. About 56 participants will be randomly assigned to receive eith…

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

This study tests whether regular blood tests (liquid biopsies) can better monitor treatment in 350 people with advanced non-small cell lung cancer who are receiving immunotherapy. The goal is to see if this approach reduces the number of ineffective treatments and unnecessary sid…

This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back i…

This study tests whether a simple blood test (ctDNA) can help doctors decide if adding chemotherapy to the immunotherapy drug cemiplimab works better for advanced lung cancer. About 63 people with stage IV or stage IIIB/C non-small cell lung cancer that hasn't been treated before…

This study looks at whether a routine MRI scan of the brain is helpful for people newly diagnosed with stage IV non-small cell lung cancer that has spread but does not yet cause brain symptoms. One hundred participants will get a brain MRI, and doctors will assess how the results…

This observational study follows 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers will collect medical data to see how long the tr…

This Italian study is collecting real-world data from 300 patients with advanced non-small cell lung cancer who are receiving a combination of nivolumab, ipilimumab, and chemotherapy as their first treatment. The goal is to see how long patients live and how long the cancer stays…